PTH and chronic kidney disease: Patients in stage 5 CKD (CKD5) with severe secondary hyperparathyroidism (SHPT) are at increased risk of cardiovascular disease and death due to increased synthesis and secretion of parathyroid hormone (PTH) [3–5].